Read This Twitter Chat About Gilead and the Cost of its Hep C Drug

Bloomberg reporter Drew Armstrong has been doing some great reporting on the controversy surrounding Gilead Sciences (GILD) and it's $1,000-a-day hepatitis C pill Sovaldi. The issues has definitely weighed some on Gilead's stock price recently. Armstrong published a new story today discussing how Medicaid providers were limiting access to Sovaldi because of its price. 

The story prompted an excellent discussion between Armstrong and ISI Group analyst Mark Schoenebaum, who's been bullish on Gilead and the Sovaldi launch. Twitter makes it hard to follow long conversation threads, so I stitched it together below:

Mark Schoenebaum (@MarkSchoenebaum) March 20, 2014

Mark Schoenebaum (@MarkSchoenebaum) March 20, 2014

Yes, Mark, you've earned your Twitter manhood badge today. Well done! 

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Centene, LabCorp Among Healthcare Stock Gainers

Centene, LabCorp Among Healthcare Stock Gainers

A Regular Winning Trade Becomes Roadkill in Market Meltdown

A Regular Winning Trade Becomes Roadkill in Market Meltdown

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside